PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of molmedLink to Publisher's site
 
Mol Med. 1999 February; 5(2): 98–109.
PMCID: PMC2230416

Rate and severity of HIV-associated dementia (HAD): correlations with Gp41 and iNOS.

Abstract

BACKGROUND: Fifteen to thirty percent of AIDS patients develop some type of neurologic disorder during the course of their illness and the vast majority of these neurologic disorders will be HIV-associated dementia (HAD). These patients can exhibit varying degrees of severity and rates of progression of HAD. Neuropathologic variables that are associated with the rate of progression of HAD are not known. MATERIALS AND METHODS: Tissue was collected at autopsy from the Johns Hopkins University HIV Neurology Program. Seventy-one AIDS patients of this prospectively characterized population were followed until death to obtain information on dementia severity and the rate of neurological progression. Immunoblot analysis of immunological nitric oxide synthase (iNOS), HAM56, gp41, p24, gp120, and beta-tubulin was performed and the levels of iNOS, HAM56, gp41, and p24 were normalized to beta-tubulin and analyzed for significance by means of the Kruskal-Wallis test for multiple groups. RESULTS: We have identified unique groups within this spectrum and designated them slow, moderate, and rapid progressors. Slow and moderate progressors' neurological progression occurs over a course of months to years, whereas the rapid progressors' disease shows rapid increases in severity over weeks to months. In the present study we demonstrate that the severity and rate of progression of HAD correlates significantly with levels of the HIV-1 coat protein, gp41, iNOS, and HAM56, a marker of microglial/macrophage activation. CONCLUSION: The severity and rate of progression of HAD correlates with indices of immune activation as well as levels of iNOS and gp41. There appears to be a threshold effect in which high levels of gp41, iNOS, and immune activation are particularly associated with severe (Memorial Sloan-Kettering score 3 to 4) and rapidly progressive HAD.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.7M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol. 1986 Jun;19(6):517–524. [PubMed]
  • Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC, Cleary P. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science. 1988 Feb 5;239(4840):586–592. [PubMed]
  • Zheng J, Gendelman HE. The HIV-1 associated dementia complex: a metabolic encephalopathy fueled by viral replication in mononuclear phagocytes. Curr Opin Neurol. 1997 Aug;10(4):319–325. [PubMed]
  • Glass JD, Fedor H, Wesselingh SL, McArthur JC. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol. 1995 Nov;38(5):755–762. [PubMed]
  • Takahashi K, Wesselingh SL, Griffin DE, McArthur JC, Johnson RT, Glass JD. Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol. 1996 Jun;39(6):705–711. [PubMed]
  • Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, Yungbluth M, Janotta F, Aksamit A, Martin MA, Fauci AS. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science. 1986 Sep 5;233(4768):1089–1093. [PubMed]
  • Dickson DW, Lee SC, Liu W, Brosnan CF. Microglial involvement in the acquired immunodeficiency syndrome (AIDS). Neuropathol Appl Neurobiol. 1994 Apr;20(2):211–213. [PubMed]
  • Tornatore C, Chandra R, Berger JR, Major EO. HIV-1 infection of subcortical astrocytes in the pediatric central nervous system. Neurology. 1994 Mar;44(3 Pt 1):481–487. [PubMed]
  • Tornatore C, Meyers K, Atwood W, Conant K, Major E. Temporal patterns of human immunodeficiency virus type 1 transcripts in human fetal astrocytes. J Virol. 1994 Jan;68(1):93–102. [PMC free article] [PubMed]
  • Everall IP, Glass JD, McArthur J, Spargo E, Lantos P. Neuronal density in the superior frontal and temporal gyri does not correlate with the degree of human immunodeficiency virus-associated dementia. Acta Neuropathol. 1994;88(6):538–544. [PubMed]
  • Wiley CA, Masliah E, Morey M, Lemere C, DeTeresa R, Grafe M, Hansen L, Terry R. Neocortical damage during HIV infection. Ann Neurol. 1991 Jun;29(6):651–657. [PubMed]
  • Masliah E, Ge N, Morey M, DeTeresa R, Terry RD, Wiley CA. Cortical dendritic pathology in human immunodeficiency virus encephalitis. Lab Invest. 1992 Mar;66(3):285–291. [PubMed]
  • Epstein LG, Gendelman HE. Human immunodeficiency virus type 1 infection of the nervous system: pathogenetic mechanisms. Ann Neurol. 1993 May;33(5):429–436. [PubMed]
  • Lipton SA, Gendelman HE. Seminars in medicine of the Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency syndrome. N Engl J Med. 1995 Apr 6;332(14):934–940. [PubMed]
  • Teo I, Veryard C, Barnes H, An SF, Jones M, Lantos PL, Luthert P, Shaunak S. Circular forms of unintegrated human immunodeficiency virus type 1 DNA and high levels of viral protein expression: association with dementia and multinucleated giant cells in the brains of patients with AIDS. J Virol. 1997 Apr;71(4):2928–2933. [PMC free article] [PubMed]
  • Pulliam L, Gascon R, Stubblebine M, McGuire D, McGrath MS. Unique monocyte subset in patients with AIDS dementia. Lancet. 1997 Mar 8;349(9053):692–695. [PubMed]
  • Brew BJ, Dunbar N, Pemberton L, Kaldor J. Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. J Infect Dis. 1996 Aug;174(2):294–298. [PubMed]
  • Sacktor NC, Bacellar H, Hoover DR, Nance-Sproson TE, Selnes OA, Miller EN, Dal Pan GJ, Kleeberger C, Brown A, Saah A, et al. Psychomotor slowing in HIV infection: a predictor of dementia, AIDS and death. J Neurovirol. 1996 Dec;2(6):404–410. [PubMed]
  • Wiley CA, Achim C. Human immunodeficiency virus encephalitis is the pathological correlate of dementia in acquired immunodeficiency syndrome. Ann Neurol. 1994 Oct;36(4):673–676. [PubMed]
  • Brew BJ. Human immunodeficiency virus in brain and correlation with dementia. Ann Neurol. 1996 Jun;39(6):828–829. [PubMed]
  • Pang S, Koyanagi Y, Miles S, Wiley C, Vinters HV, Chen IS. High levels of unintegrated HIV-1 DNA in brain tissue of AIDS dementia patients. Nature. 1990 Jan 4;343(6253):85–89. [PubMed]
  • Brew BJ, Pemberton L, Cunningham P, Law MG. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis. 1997 Apr;175(4):963–966. [PubMed]
  • Adamson DC, Wildemann B, Sasaki M, Glass JD, McArthur JC, Christov VI, Dawson TM, Dawson VL. Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 gp41. Science. 1996 Dec 13;274(5294):1917–1921. [PubMed]
  • Wiley CA, Nelson JA. Human immunodeficiency virus: infection of the nervous system. Curr Top Microbiol Immunol. 1990;160:157–172. [PubMed]
  • Nuovo GJ, Alfieri ML. AIDS dementia is associated with massive, activated HIV-1 infection and concomitant expression of several cytokines. Mol Med. 1996 May;2(3):358–366. [PMC free article] [PubMed]
  • Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med. 1995 Sep 21;333(12):751–756. [PubMed]
  • Operskalski EA, Stram DO, Lee H, Zhou Y, Donegan E, Busch MP, Stevens CE, Schiff ER, Dietrich SL, Mosley JW. Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. Transfusion Safety Study Group. J Infect Dis. 1995 Sep;172(3):648–655. [PubMed]
  • Saah AJ, Muñoz A, Kuo V, Fox R, Kaslow RA, Phair JP, Rinaldo CR, Jr, Detels R, Polk BF. Predictors of the risk of development of acquired immunodeficiency syndrome within 24 months among gay men seropositive for human immunodeficiency virus type 1: a report from the Multicenter AIDS Cohort Study. Am J Epidemiol. 1992 May 15;135(10):1147–1155. [PubMed]
  • von Overbeck J, Egger M, Smith GD, Schoep M, Ledergerber B, Furrer H, Malinverni R. Survival in HIV infection: do sex and category of transmission matter? Swiss HIV Cohort Study. AIDS. 1994 Sep;8(9):1307–1313. [PubMed]
  • Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol. 1986 Jun;19(6):517–524. [PubMed]
  • McArthur JC. Neurologic manifestations of AIDS. Medicine (Baltimore) 1987 Nov;66(6):407–437. [PubMed]
  • Portegies P, Enting RH, de Gans J, Algra PR, Derix MM, Lange JM, Goudsmit J. Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands. AIDS. 1993 May;7(5):669–675. [PubMed]
  • Tozzi V, Narciso P, Galgani S, Sette P, Balestra P, Gerace C, Pau FM, Pigorini F, Volpini V, Camporiondo MP, et al. Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex. AIDS. 1993 May;7(5):683–692. [PubMed]
  • Bouwman FH, Skolasky RL, Hes D, Selnes OA, Glass JD, Nance-Sproson TE, Royal W, Dal Pan GJ, McArthur JC. Variable progression of HIV-associated dementia. Neurology. 1998 Jun;50(6):1814–1820. [PubMed]
  • Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis. 1988 Nov;158(5):1079–1083. [PubMed]
  • Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–198. [PubMed]
  • Power C, McArthur JC, Johnson RT, Griffin DE, Glass JD, Perryman S, Chesebro B. Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol. 1994 Jul;68(7):4643–4649. [PMC free article] [PubMed]
  • Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature. 1994 Jan 13;367(6459):188–193. [PubMed]
  • Hill JM, Mervis RF, Avidor R, Moody TW, Brenneman DE. HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates. Brain Res. 1993 Feb 19;603(2):222–233. [PubMed]
  • Bukrinsky MI, Nottet HS, Schmidtmayerova H, Dubrovsky L, Flanagan CR, Mullins ME, Lipton SA, Gendelman HE. Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease. J Exp Med. 1995 Feb 1;181(2):735–745. [PMC free article] [PubMed]
  • Bagasra O, Bobroski L, Sarker A, Bagasra A, Saikumari P, Pomerantz RJ. Absence of the inducible form of nitric oxide synthase in the brains of patients with the acquired immunodeficiency syndrome. J Neurovirol. 1997 Apr;3(2):153–167. [PubMed]
  • Levy JA. The transmission of HIV and factors influencing progression to AIDS. Am J Med. 1993 Jul;95(1):86–100. [PubMed]
  • Galli RA, Castriciano S, Fearon M, Major C, Choi KW, Mahony J, Chernesky M. Performance characteristics of recombinant enzyme immunoassay to detect antibodies to human immunodeficiency virus type 1 (HIV-1) and HIV-2 and to measure early antibody responses in seroconverting patients. J Clin Microbiol. 1996 Apr;34(4):999–1002. [PMC free article] [PubMed]
  • Pudney J, Anderson D. Effects of fixation and paraffin embedding on the immunohistological detection of cell-associated HIV-1 by different monoclonal antibodies. J Histochem Cytochem. 1995 Sep;43(9):857–862. [PubMed]
  • Portincasa P, Conti G, Zannino T, Visalli S, Chezzi C. Radioimmune western blotting in comparison with conventional western blotting, second and third generation ELISA assays for the serodiagnosis of HIV-1 infection. New Microbiol. 1994 Jul;17(3):169–176. [PubMed]
  • Flaherty MT, Hauer DA, Mankowski JL, Zink MC, Clements JE. Molecular and biological characterization of a neurovirulent molecular clone of simian immunodeficiency virus. J Virol. 1997 Aug;71(8):5790–5798. [PMC free article] [PubMed]
  • Bird C, Burke J, Gleeson PA, McCluskey J. Expression of human immunodeficiency virus 1 (HIV-1) envelope gene products transcribed from a heterologous promoter. Kinetics of HIV-1 envelope processing in transfected cells. J Biol Chem. 1990 Nov 5;265(31):19151–19157. [PubMed]
  • Egan MA, Carruth LM, Rowell JF, Yu X, Siliciano RF. Human immunodeficiency virus type 1 envelope protein endocytosis mediated by a highly conserved intrinsic internalization signal in the cytoplasmic domain of gp41 is suppressed in the presence of the Pr55gag precursor protein. J Virol. 1996 Oct;70(10):6547–6556. [PMC free article] [PubMed]
  • Koka P, He K, Camerini D, Tran T, Yashar SS, Merrill JE. The mapping of HIV-1 gp160 epitopes required for interleukin-1 and tumor necrosis factor alpha production in glial cells. J Neuroimmunol. 1995 Mar;57(1-2):179–191. [PubMed]
  • Koka P, He K, Zack JA, Kitchen S, Peacock W, Fried I, Tran T, Yashar SS, Merrill JE. Human immunodeficiency virus 1 envelope proteins induce interleukin 1, tumor necrosis factor alpha, and nitric oxide in glial cultures derived from fetal, neonatal, and adult human brain. J Exp Med. 1995 Oct 1;182(4):941–951. [PMC free article] [PubMed]
  • Rabenstein MD, Shin YK. HIV-1 gp41 tertiary structure studied by EPR spectroscopy. Biochemistry. 1996 Nov 5;35(44):13922–13928. [PubMed]
  • Wingfield PT, Stahl SJ, Kaufman J, Zlotnick A, Hyde CC, Gronenborn AM, Clore GM. The extracellular domain of immunodeficiency virus gp41 protein: expression in Escherichia coli, purification, and crystallization. Protein Sci. 1997 Aug;6(8):1653–1660. [PubMed]
  • Adamson DC, Kopnisky KL, Dawson TM, Dawson VL. Mechanisms and structural determinants of HIV-1 coat protein, gp41-induced neurotoxicity. J Neurosci. 1999 Jan 1;19(1):64–71. [PubMed]

Articles from Molecular Medicine are provided here courtesy of The Feinstein Institute for Medical Research at North Shore LIJ